Volume 9, Number 1—January 2003
Perspective
Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors
W. Michael Scheld*
Table 3
Mutant prevention concentrations (MPC)a for various fluoroquinolones to Streptococcus pneumoniae and Pseudomonas aeruginosab
| Fluoroquinolone | Daily dose (mg) | Cmaxc (mg/L) | P. aeruginosa MPC (mg/L) | S. pneumoniae MPC (mg/L) |
|---|---|---|---|---|
| Ciprofloxacin |
500 b.i.d. |
3.0 |
2 |
NRd |
| 750 b.i.d. |
3.6 |
2 |
NR |
|
| Levofloxacin |
500 q.d. |
5.7 |
8 |
8 |
| Moxifloxacin |
400 q.d. |
4.5 |
NR |
2 |
| Gatifloxacin | 400 q.d. | 4.2 | NR | 4 |
aMPC values are derived from a study of approximately 100 isolates and are considered provisional.
bSee references 47 and 48 for S. pneumoniae and P. aeruginosa, respectively.
cCmax, peak serum concentration of the drug (41–44).
dNR, not reported.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.